Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

a protein implicated in neurodegenerative diseases like Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Improved technologies for small molecules ...

Over the course of one year, MRI with deep-learning segmentation revealed significant brain volume reduction in MSA ROIs whereas Parkinson’s disease patients showed no significant brain volume ...

The drug used to treat Parkinson's disease, most notably levodopa (SINEMET) , is also prescribed for MSA individuals. However, the efficacy of such medications varies greatly among the affected ...